These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38995718)

  • 1. Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy.
    Einstein DJ; Halbert B; Denize T; Matar S; West DJ; Gupta M; Andrianopoulos E; Seery V; Herman C; Onimus K; Wells A; Bunch B; Signoretti S; Natarajan A; Veerapathran A; McDermott DF
    J Immunother; 2024 Nov-Dec 01; 47(9):361-368. PubMed ID: 38995718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
    Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
    Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
    Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
    Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
    Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
    Baine MK; Turcu G; Zito CR; Adeniran AJ; Camp RL; Chen L; Kluger HM; Jilaveanu LB
    Oncotarget; 2015 Sep; 6(28):24990-5002. PubMed ID: 26317902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
    Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
    Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
    Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
    Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
    Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
    J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
    J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cells Expanded from PD-1
    Li T; Zhao L; Yang Y; Wang Y; Zhang Y; Guo J; Chen G; Qin P; Xu B; Ma B; Zhang F; Shang Y; Li Q; Zhang K; Yuan D; Feng C; Ma Y; Liu Z; Tian Z; Li H; Wang S; Gao Q
    Cancer Res; 2021 Apr; 81(8):2184-2194. PubMed ID: 33408117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy.
    Choi S; Hossain M; Lee H; Baek J; Park HS; Lim CL; Han D; Park T; Kim JH; Gong G; Kweon MN; Lee HJ
    Cancer Immunol Immunother; 2024 Apr; 73(6):101. PubMed ID: 38630265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression and infiltration by CD4
    Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
    Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
    Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
    Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
    Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.